More than 150 lawsuits already have been filed against manufacturers of low testosterone therapy drugs in the U.S. District Court for the Northern District of Illinois. This is the court in which low-T drug litigation has been consolidated into what is called "multidistrict litigation (MDL)" in the federal court system.
Phoenix attorney Jonathan O'Steen has asked the federal Food and Drug Administration (FDA) to take action to prevent off-label use of the testosterone therapy drugs AndroGel, AndroDerm, Axiron, Bio-T-Gel, Delatestryl, Depo-Testosterone, Fortesta, Striant, Testim and Testopel.
In June, all testosterone therapy lawsuits previously filed in various federal courts throughout the United States were consolidated in a single court—the U.S. District Court for the Northern District of Illinois. The advantages of consolidation include efficiency, resource conservation, reduction of duplication in the trial preparation process and elimination of the possibility of conflicting rulings among different courts.